{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T08:06:54Z","timestamp":1767859614961,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Collegium Pharmaceuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s40261-023-01248-9","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T17:03:07Z","timestamp":1677690187000},"page":"197-203","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Cross-Sectional Study of Tampering in Xtampza ER, an Abuse-Deterrent Formulation of an Extended-Release Opioid, in a Treatment Center Population"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6434-529X","authenticated-orcid":false,"given":"Jennifer","family":"Jewell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Black","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janetta","family":"Iwanicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Dart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,1]]},"reference":[{"issue":"12","key":"1248_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0167499","volume":"11","author":"JL Iwanicki","year":"2016","unstructured":"Iwanicki JL, et al. Abuse and diversion of immediate release opioid analgesics as compared to extended release formulations in the United States. PLoS\u00a0One. 2016;11(12): e0167499.","journal-title":"PLoS\u00a0One"},{"issue":"4","key":"1248_CR2","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1001\/jamainternmed.2018.6989","volume":"179","author":"GP Guy Jr","year":"2019","unstructured":"Guy GP Jr, et al. County-level opioid prescribing in the United States, 2015 and 2017. JAMA Intern Med. 2019;179(4):574\u20136.","journal-title":"JAMA Intern Med"},{"issue":"2","key":"1248_CR3","doi-asserted-by":"publisher","first-page":"244","DOI":"10.2105\/AJPH.2019.305412","volume":"110","author":"TJ Cicero","year":"2020","unstructured":"Cicero TJ, Ellis MS, Kasper ZA. Polysubstance use: a broader understanding of substance use during the opioid crisis. Am J Public Health. 2020;110(2):244\u201350.","journal-title":"Am J Public Health"},{"issue":"1","key":"1248_CR4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/pds.4078","volume":"26","author":"TJ Cicero","year":"2017","unstructured":"Cicero TJ, Ellis MS, Kasper ZA. Relative preferences in the abuse of immediate-release versus extended-release opioids in a sample of treatment-seeking opioid abusers. Pharmacoepidemiol Drug Saf. 2017;26(1):56\u201362.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"1248_CR5","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3109\/00952990.2011.569623","volume":"37","author":"N Katz","year":"2011","unstructured":"Katz N, et al. Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions. Am J Drug Alcohol Abuse. 2011;37(4):205\u201317.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"1248_CR6","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.drugalcdep.2017.01.039","volume":"175","author":"JL Green","year":"2017","unstructured":"Green JL, et al. Medical outcomes associated with prescription opioid abuse via oral and non-oral routes of administration. Drug Alcohol Depend. 2017;175:140\u20135.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"1248_CR7","doi-asserted-by":"publisher","DOI":"10.2196\/21212","volume":"23","author":"D Balsamo","year":"2021","unstructured":"Balsamo D, et al. Patterns of routes of administration and drug tampering for nonmedical opioid consumption: data mining and content analysis of reddit discussions. J Med Internet Res. 2021;23(1): e21212.","journal-title":"J Med Internet Res"},{"issue":"2","key":"1248_CR8","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S2215-0366(18)30003-8","volume":"5","author":"B Larance","year":"2018","unstructured":"Larance B, et al. The effect of a potentially tamper-resistant oxycodone formulation on opioid use and harm: main findings of the National Opioid Medications Abuse Deterrence (NOMAD) study. Lancet Psychiatry. 2018;5(2):155\u201366.","journal-title":"Lancet Psychiatry"},{"issue":"6","key":"1248_CR9","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1097\/j.pain.0000000000000511","volume":"157","author":"TJ Cicero","year":"2016","unstructured":"Cicero TJ, Ellis MS, Kasper ZA. A tale of 2 ADFs: differences in the effectiveness of abuse-deterrent formulations of oxymorphone and oxycodone extended-release drugs. Pain. 2016;157(6):1232\u20138.","journal-title":"Pain"},{"key":"1248_CR10","volume-title":"Abuse-deterrent opioids\u2014evaluation and labeling: guidance for industry","author":"US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research","year":"2015","unstructured":"US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. Abuse-deterrent opioids\u2014evaluation and labeling: guidance for industry. Silver Spring: Department of Health and Human Services; 2015."},{"issue":"1","key":"1248_CR11","first-page":"21","volume":"13","author":"A Petrilla","year":"2020","unstructured":"Petrilla A, et al. Association between formulary coverage and use of abuse-deterrent prescription opioids, risk for abuse or overdose, and associated healthcare resource utilization. Am Health Drug Benefits. 2020;13(1):21\u201331.","journal-title":"Am Health Drug Benefits"},{"issue":"2","key":"1248_CR12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.0216","volume":"1","author":"CS Hwang","year":"2018","unstructured":"Hwang CS, et al. Patterns of immediate-release and extended-release opioid analgesic use in the management of chronic pain, 2003\u20132014. JAMA Netw Open. 2018;1(2): e180216.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"1248_CR13","doi-asserted-by":"publisher","first-page":"233","DOI":"10.5055\/jom.2014.0211","volume":"10","author":"EA Kopecky","year":"2014","unstructured":"Kopecky EA, et al. Impact of physical manipulation on in vitro and in vivo release profiles of oxycodone DETERx\u00ae: an extended-release, abuse-deterrent formulation. J Opioid Manag. 2014;10(4):233\u201346.","journal-title":"J Opioid Manag"},{"issue":"6","key":"1248_CR14","first-page":"1112","volume":"17","author":"LR Webster","year":"2016","unstructured":"Webster LR, et al. A randomized, double-blind, double-dummy study to evaluate the intranasal human abuse potential and pharmacokinetics of a novel extended-release abuse-deterrent formulation of oxycodone. Pain Med. 2016;17(6):1112\u201330.","journal-title":"Pain Med"},{"issue":"3","key":"1248_CR15","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s40471-018-0155-y","volume":"5","author":"M D'Arcy","year":"2018","unstructured":"D\u2019Arcy M, St\u00fcrmer T, Lund JL. The importance and implications of comparator selection in pharmacoepidemiologic research. Curr Epidemiol Rep. 2018;5(3):272\u201383.","journal-title":"Curr Epidemiol Rep"},{"issue":"3","key":"1248_CR16","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMsa1406143","volume":"372","author":"RC Dart","year":"2015","unstructured":"Dart RC, et al. Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med. 2015;372(3):241\u20138.","journal-title":"N Engl J Med"},{"key":"1248_CR17","unstructured":"McDaniel H et al. Comparing prescription opioids, methadone, and heroin endorsement rates from the treatment episode data set to the RADARS system treatment center programs. RADARS\u00ae System Technical Report; 2016. p. Q3."},{"key":"1248_CR18","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1471-2288-5-28","volume":"5","author":"M H\u00f6fler","year":"2005","unstructured":"H\u00f6fler M. Causal inference based on counterfactuals. BMC Med Res Methodol. 2005;5:28.","journal-title":"BMC Med Res Methodol"},{"issue":"5","key":"1248_CR19","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1093\/pm\/pnx022","volume":"19","author":"J Pergolizzi","year":"2018","unstructured":"Pergolizzi J, Kowalski M, He E. Effectiveness and safety of once-daily extended-release hydrocodone in individuals previously receiving immediate-release oxycodone for chronic pain. Pain Med. 2018;19(5):967\u201377.","journal-title":"Pain Med"},{"key":"1248_CR20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1477-7517-8-29","volume":"8","author":"SF Butler","year":"2011","unstructured":"Butler SF, et al. Abuse risks and routes of administration of different prescription opioid compounds and formulations. Harm Reduct J. 2011;8:29.","journal-title":"Harm Reduct J"},{"issue":"9","key":"1248_CR21","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1007\/s00213-021-05872-1","volume":"238","author":"S Babalonis","year":"2021","unstructured":"Babalonis S, et al. Relative potency of intravenous oxymorphone compared to other \u00b5 opioid agonists in humans\u2014pilot study outcomes. Psychopharmacology. 2021;238(9):2503\u201314.","journal-title":"Psychopharmacology"},{"issue":"3","key":"1248_CR22","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJMoa1515195","volume":"375","author":"PJ Peters","year":"2016","unstructured":"Peters PJ, et al. HIV infection linked to injection use of oxymorphone in Indiana, 2014\u20132015. N Engl J Med. 2016;375(3):229\u201339.","journal-title":"N Engl J Med"},{"key":"1248_CR23","volume-title":"RStudio: integrated development for R","author":"RStudio Team","year":"2021","unstructured":"RStudio Team. RStudio: integrated development for R. Boston: RStudio, PBC; 2021."},{"key":"1248_CR24","unstructured":"Mattson CL, et al. Trends and geographic patterns in drug and synthetic opioid overdose deaths\u2014United States, 2013\u20132019. In: Morbidity and Mortality Weekly Report. US Department of Health and Human Services\/Centers for Disease Control and Prevention."},{"key":"1248_CR25","unstructured":"Substance Abuse and Mental Health Services Administration, Key Substance Use and Mental Health Indicators in the United States: results from the 2020 National Survey on Drug Use and Health. Rockville: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2021."},{"issue":"12","key":"1248_CR26","doi-asserted-by":"publisher","first-page":"3660","DOI":"10.1093\/pm\/pnaa272","volume":"21","author":"SG Severtson","year":"2020","unstructured":"Severtson SG, et al. Postmarketing analysis of misuse, abuse, and diversion of Xtampza ER. Pain Med. 2020;21(12):3660\u20138.","journal-title":"Pain Med"},{"issue":"7","key":"1248_CR27","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s40261-018-0651-3","volume":"38","author":"AJ Salwan","year":"2018","unstructured":"Salwan AJ, Hagemeier NE, Harirforoosh S. Abuse-deterrent opioid formulations: a key ingredient in the recipe to prevent opioid disasters? Clin Drug Investig. 2018;38(7):573\u20137.","journal-title":"Clin Drug Investig"},{"issue":"6","key":"1248_CR28","doi-asserted-by":"publisher","first-page":"353","DOI":"10.5055\/jom.2017.0402","volume":"13","author":"RE Brown Jr","year":"2017","unstructured":"Brown RE Jr. Abuse-deterrent formulations of opioids: many questions still to answer. J Opioid Manag. 2017;13(6):353\u20136.","journal-title":"J Opioid Manag"}],"updated-by":[{"DOI":"10.1007\/s40261-023-01259-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T00:00:00Z","timestamp":1681171200000}}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01248-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-023-01248-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01248-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T12:18:43Z","timestamp":1681215523000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-023-01248-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["1248"],"URL":"https:\/\/doi.org\/10.1007\/s40261-023-01248-9","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40261-023-01259-6","asserted-by":"object"}]},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"30 January 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2023","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40261-023-01259-6","URL":"https:\/\/doi.org\/10.1007\/s40261-023-01259-6","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by Collegium Pharmaceutical. Collegium did not participate in the analysis or drafting of this manuscript. Collegium Pharmaceutical reviewed only for proprietary information.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The RADARS System is supported by subscriptions from pharmaceutical manufacturers, government and non-government agencies for surveillance, research, and reporting services. RADARS System is the property of Denver Health and Hospital Authority, a political subdivision of the State of Colorado. Denver Health retains exclusive ownership of all data, databases, and systems.\u00a0All authors have no other conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The protocol for the Opioid Treatment Program was originally approved on 11 May 2004 by the Institutional Review Board at the National Development and Research Institute with the most recent authorization provided on 02 March 2022 by Colorado Multiple Institutional Review Board (COMIRB). The protocol for the Survey of Key Informants' Patients Program was originally approved on 28 September 2006 by the WUSTL Human Research Protection Office, with the most recent authorization provided on 22 March 2022.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data are not available for release.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"JJ contributed to the study design, analysis plan, interpretation, and writing. JB contributed to the study design, analysis plan, interpretation, and writing. ME contributed to the interpretation and writing. HO conducted the analyses and contributed to the study design, analysis plan, and writing. JI contributed to the interpretation, writing, and review. RD contributed to the interpretation, writing, and review.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}